Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Prenetics Holding Company Limited (PRENW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/05/2025: PRENW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -50% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/05/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.17 | 52 Weeks Range 0.01 - 0.05 | Updated Date 06/21/2025 |
52 Weeks Range 0.01 - 0.05 | Updated Date 06/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -11.04 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -115.91% | Operating Margin (TTM) -61.41% |
Management Effectiveness
Return on Assets (TTM) -14.52% | Return on Equity (TTM) -28.48% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 9154745 |
Shares Outstanding - | Shares Floating 9154745 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Prenetics Holding Company Limited
Company Overview
History and Background
Prenetics Holding Company Limited was founded in 2014. It has grown to become a leading global diagnostics and genetics testing company. Significant milestones include its expansion into various international markets and its development of innovative testing solutions, particularly in response to global health events.
Core Business Areas
- Diagnostic Testing: Prenetics offers a comprehensive suite of diagnostic tests, including those for infectious diseases, cancer biomarkers, and general health screenings. This segment leverages advanced laboratory infrastructure and molecular diagnostics.
- Genetic Testing: The company provides a range of genetic testing services, including ancestry, health predisposition, and pharmacogenomic testing. These services aim to empower individuals with insights into their genetic makeup for personalized health and wellness.
- Enterprise Solutions: Prenetics partners with businesses and governments to provide large-scale testing solutions, such as COVID-19 testing programs for organizations and travel. This segment focuses on efficiency, scalability, and compliance.
Leadership and Structure
Prenetics Holding Company Limited is led by a management team with expertise in healthcare, biotechnology, and business operations. The company operates with a divisional structure, with dedicated teams for R&D, sales and marketing, laboratory operations, and corporate functions.
Top Products and Market Share
Key Offerings
- COVID-19 Testing Solutions: Prenetics has been a significant provider of COVID-19 testing services, including PCR and antigen tests. While the demand for COVID-19 testing has fluctuated, Prenetics has established a strong presence in this market, serving both individual consumers and enterprise clients. Competitors include numerous diagnostic labs and biotech companies globally.
- CircleDNA: CircleDNA is a comprehensive at-home DNA testing service that provides insights into health, wellness, ancestry, and nutrition. It is one of Prenetics' flagship consumer products. Competitors include 23andMe, AncestryDNA, and other direct-to-consumer genetic testing services.
- Health Screening and Diagnostic Tests: Prenetics offers a broad portfolio of general health screening tests and specialized diagnostic tests for various medical conditions. These are offered through its laboratory network. Competitors are diverse, ranging from large hospital systems to specialized diagnostic laboratories.
Market Dynamics
Industry Overview
Prenetics operates within the rapidly growing global diagnostics and genomics market. Key trends include increasing demand for personalized medicine, advancements in molecular diagnostics, and a greater consumer interest in proactive health management. The market is also influenced by regulatory environments and public health initiatives.
Positioning
Prenetics is positioned as a global leader in diagnostics and genetics, leveraging its integrated platform that spans from at-home testing to advanced laboratory services. Its competitive advantages include its diversified service offerings, technological innovation, and established presence in key markets. The company has also demonstrated agility in responding to emerging health needs, such as during the COVID-19 pandemic.
Total Addressable Market (TAM)
The global diagnostics market is valued in the hundreds of billions of dollars and continues to grow. The genomics market is also expanding rapidly, with projections reaching tens of billions of dollars. Prenetics is positioned to capture a portion of this TAM through its diverse product and service portfolio, targeting both consumer and enterprise segments.
Upturn SWOT Analysis
Strengths
- Diversified product and service portfolio.
- Strong R&D capabilities and technological innovation.
- Global presence and established distribution networks.
- Agility in responding to market demands (e.g., COVID-19 testing).
- Experienced leadership team.
Weaknesses
- Dependence on specific testing markets (e.g., COVID-19).
- Brand recognition may vary across different regions.
- Potential for high operational costs associated with advanced labs.
- Competition from established players and emerging startups.
Opportunities
- Growth in personalized medicine and preventative healthcare.
- Expansion into new geographic markets.
- Development of novel diagnostic and genetic testing technologies.
- Strategic partnerships and acquisitions.
- Increasing consumer adoption of at-home health solutions.
Threats
- Changes in regulatory policies and reimbursement rates.
- Intensifying competition and price pressures.
- Technological disruptions from competitors.
- Economic downturns affecting consumer spending on healthcare.
- Data privacy and security concerns related to genetic information.
Competitors and Market Share
Key Competitors
- Quest Diagnostics (DGX)
- Labcorp Drug Development (LH)
- Myriad Genetics (MYGN)
- Exact Sciences Corporation (EXAS)
Competitive Landscape
Prenetics competes in a fragmented market with larger, established diagnostic companies, as well as specialized genetic testing firms and emerging biotech startups. Its advantages lie in its integrated platform and focus on consumer-facing solutions, while disadvantages might include brand recognition and scale compared to some giants in the industry.
Growth Trajectory and Initiatives
Historical Growth: Prenetics has demonstrated significant historical growth, fueled by its expansion into new markets, product development, and its role in providing essential testing services during global health crises. Its growth trajectory has been marked by strategic investments and operational scaling.
Future Projections: Future growth projections for Prenetics are likely to be influenced by the increasing demand for personalized health solutions, advancements in genomic sequencing, and potential expansion into new therapeutic areas or diagnostic applications. Analyst estimates would provide specific quantitative forecasts.
Recent Initiatives: Recent initiatives may include strategic partnerships to expand market reach, investments in new laboratory technologies, and the development of innovative consumer-facing health platforms. The company also focuses on leveraging its data analytics capabilities to enhance its service offerings.
Summary
Prenetics Holding Company Limited is a growing diagnostics and genetics company with a diversified portfolio and global reach. Its strengths lie in its technological innovation and adaptability, particularly evident during the pandemic. However, it faces intense competition and potential market volatility in specialized testing segments. The company needs to continuously innovate and strategically expand its market presence while navigating regulatory landscapes to sustain its growth trajectory.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company's official website and press releases.
- SEC filings (e.g., 10-K, 10-Q) for financial data.
- Reputable financial news outlets and market research reports.
- Stock market data providers for historical price information.
Disclaimers:
This analysis is based on publicly available information and may not encompass all aspects of Prenetics Holding Company Limited's operations or future prospects. Financial data and market share estimates are subject to change and may require further verification. This information is for informational purposes only and does not constitute financial advice. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Prenetics Holding Company Limited
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2022-05-18 | Co-Founder, Chairperson & CEO Mr. Sheng Wu Yeung | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 285 | Website https://www.prenetics.com |
Full time employees 285 | Website https://www.prenetics.com | ||
Prenetics Global Limited, a consumer health company, focuses on empowering individuals to take control of their health through science-backed solutions in Hong Kong, Taiwan, the United States, and internationally. The company operates in three segments: Prevention, Diagnostics, and Consumer Health. It operates IM8 Health that sells health and wellness products; and provides fulfillment and distribution services for sports nutrition products under the Consumer Health segment. The company is also involved in the operation of CircleDNA, a consumer genetic testing brand that uses next-generation sequencing (NGS) technology to provide comprehensive insights into health, wellness, and genetic predispositions under Prevention segment.; and ACT Genomics that provides precision oncology testing services under the Diagnostics segment. In addition, it develops and commercializes multi-cancer early detection technologies. Further, the company offers a range of genomic profiling panels tailored for requirements and clinician needs. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.